Retraction: Epidermal growth factor-stimulated human cervical cancer cell growth is associated with EGFR and cyclin D1 activation, independent of COX-2 expression levels (International Journal of Oncology (2012) 40 (13-20) DOI: 10.3892/ijo.2011.1211);Epidermal growth factor-stimulated human cervical cancer cell growth is associated with EGFR and cyclin D1 activation, independent of COX-2 expression levels

International Journal of Oncology

Volumn 40, Issue 1, 2012, Pages 13-20

  Narayanan, Rajkishen ^a   Kim, Hye Na ^a   Narayanan, Narayanan K ^a   Nargi, Dominick ^a   Narayanan, Bhagavathi A ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cervical cancer; COX 2; Cyclin D; EGFR; Human papillomavirus

Indexed keywords

CYCLIN D1; CYCLOOXYGENASE 2; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; SMALL INTERFERING RNA;

ARTICLE; CANCER CELL; CANCER GROWTH; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CELL STIMULATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DNA SYNTHESIS; GENE SILENCING; HUMAN; HUMAN TISSUE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; UTERINE CERVIX CANCER; WART VIRUS; WESTERN BLOTTING;

EID: 84455174523     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2016.3737     Document Type: Erratum

References (30)

1. Muñoz N, Bosch FX, de Sanjosé S, Herrero R, Castellsagué X, Shah KV, Snijders PJ and Meijer CJ: International Agency for Research on Cancer multicenter cervical cancer study group. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348: 518-527, 2003. (Pubitemid 36159887)
2. Zur Hausen H: Papillomaviruses in human cancers. Mol Carcinog 1: 147-150, 1988.
3. Zur Hausen H: Papillomaviruses causing cancer: Evasion from host-cell control in early events in carcinogenesis. J Natl Cancer Inst 92: 690-698, 2000.
4. Zur Hausen H: Papillomaviruses and cancer: from basic studies to clinical applications. Nat Rev Cancer 2: 342-350, 2002.
5. Clarke B and Chetty R: Cell cycle aberrations in the pathogenesis of squamous cell carcinoma of the uterine cervix. Gynecol Oncol 82: 238-246, 2001. (Pubitemid 32730597)
6. Subbaramaiah K and Dannenberg AJ: Cyclooxygenase-2 transcription is regulated by human papillomavirus 16 E6 and E7 oncoproteins: evidence of a corepressor/coactivator exchange. Cancer Res 67: 3976-3985, 2007. (Pubitemid 46762188)
7. Kim SH, Oh JM, No JH, Bang YJ, Juhnn YS and Song YS: Involvement of NF-kappaB and AP-1 in COX-2 upregulation by human papillomavirus 16 E5 oncoprotein. Carcinogenesis 30: 753-757, 2009.
8. Yokota K, Kusaka M, Ohshima T, Yamamoto S, Kurihara N, Yoshino T and Kumegawa M: Stimulation of prostaglandin E2 synthesis in cloned osteoblastic cells of mouse (MC3T3-E1) by epidermal growth factor. J Biol Chem 261: 15410-15415, 1986. (Pubitemid 17208759)
9. Fogarty GB, Conus NM, Chu J and McArthur G: Characterization of the expression and activation of the epidermal growth factor receptor in squamous cell carcinoma of the skin. Br J Dermatol 156: 92-98, 2007. (Pubitemid 44924151)
10. Jalili A, Pinc A, Pieczkowski F, Karlhofer FM, Stingl G and Wagner SN: Combination of an EGFR blocker and a COX-2 inhibitor for the treatment of advanced cutaneous squamous cell carcinoma. J Dtsch Dermatol Ges 6: 1066-1069, 2008.
11. Sales KJ, Katz AA, Davis M, Hinz S, Soeters RP, Hofmeyr MD, Millar RP and Jabbour HN: Cyclooxygenase-2 expression and prostaglandin E(2) synthesis are up-regulated in carcinomas of the cervix: a possible autocrine/paracrine regulation of neoplastic cell function via EP2/EP4 receptors. J Clin Endocrinol Metab 86: 2243-2249, 2001. (Pubitemid 32472947)
12. Narayanan BA, Narayanan NK, Davis L and Nargi D: RNA interference- mediated cyclooxygenase-2 inhibition prevents prostate cancer cell growth and induces differentiation: modulation of neuronal protein synaptophysin, cyclin D1, and androgen receptor. Mol Cancer Ther 5: 1117-1125, 2006. (Pubitemid 43881303)
13. Narayanan BA, Condon MS, Bosland MC, Reddy BS, Pittman B and Narayanan NK: Suppression of N-methyl-N-nitrosourea (MNU)/testosterone-induced rat prostate cancer growth by celecoxib: Effects on COX-2, cell cycle regulation and apoptosis mechanism(s). Clin Cancer Res 9: 3503-3513, 2003. (Pubitemid 37082750)
14. Miller RG: Simultaneous statistical inference. 2nd edition. Springer-Verlag, New York, pp37-47, 1981.
15. Cooper JA and Howell B: The when and how of Src regulation. Cell 73: 1051-1054, 1993. (Pubitemid 23180479)
16. Emlet DR, Moscatello DK, Ludlow LB and Wong AJ: Subsets of epidermal growth factor receptors during activation and endocytosis. J Biol Chem 272: 4079-4086, 1997. (Pubitemid 27078471)
17. Rojas M, Yao S and Lin YZ: Controlling epidermal growth factor (EGF)-stimulated Ras activation in intact cells by a cellpermeable peptide mimicking phosphorylated EGF receptor. J Biol Chem 271: 27456-24761, 1996.
18. Almadori G, Cadoni G, Cattani P, Galli J, Bussu F, Ferrandina G, Scambia G, Fadda G and Maurizi M: Human papillomavirus infection and epidermal growth factor receptor expression in primary laryngeal squamous cell carcinoma. Clin Cancer Res 7: 3988-3993, 2001. (Pubitemid 34044617)
19. Fosslien E: Biochemistry of cyclooxygenase (COX)-2 inhibitors and molecular pathology of COX-2 in neoplasia. Crit Rev Clin Lab Sci 37: 431-502, 2000.
20. Brake T, Connor JP, Petereit DG and Lambert PF: Comparative analysis of cervical cancer in women and in a human papillomavirus-transgenic mouse model: identification of minichromosome maintenance protein 7 as an informative biomarker for human cervical cancer. Cancer Res 63: 8173-8180, 2003. (Pubitemid 37549465)
21. Robles AI, Rodriguez-Puebla ML, Glick AB, Trempus C, Hansen L, Sicinski P, Tennant RW, Weinberg RA, Yuspa SH and Conti CJ: Reduced skin tumor development in cyclin D1- deficient mice highlights the oncogenic ras pathway in vivo. Genes Dev 12: 2469-2474, 1998. (Pubitemid 28406950)
22. Levin ER: Bidirectional signaling between the estrogen receptor and the epidermal growth factor receptor. Mol Endocrinol 17: 309-317, 2003.
23. Reissmann PT, Koga H, Figlin RA, Holmes EC and Slamon DJ: Amplification and overexpression of the cyclin D1 and epidermal growth factor receptor genes in non-small-cell lung cancer. Lung cancer study group. J Cancer Res Clin Oncol 125: 61-70, 1999. (Pubitemid 29161456)
24. Sherr CJ: Mammalian G1 cyclins and cell cycle progression. Proc Assoc Am Physicians 107: 181-186, 1995.
25. Lee RJ, Albanese C, Fu M, D' Amico M, Lin B, Watanabe G, Haines GK III, Siegel PM, Hung MC, Yarden Y, Horowitz J, Muller WJ and Pestell RG: Cyclin D1 is required for transformation by activated Neu and is induced through an E2Fdepedent signaling pathway. Mol Cell Biol 20: 672-683, 2000. (Pubitemid 30023109)
26. Rubin Grandis J, Melhem MF, Gooding WE, Day R, Holst VA, Wagener MM, Drenning SD and Tweardy DJ: Levels of TGFalpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 90: 824-832, 1998. (Pubitemid 28280548)
27. Kalyankrishna S and Grandis JR: Epidermal growth factor receptor biology in head and neck cancer. J Clin Oncol 24: 2666-2672, 2006. (Pubitemid 46622088)
28. Kim GE, Kim YB, Cho NH, Chung HC, Pyo HR, Lee JD, Park TK, Koom WS, Chun M and Suh CO: Synchronous coexpression of epidermal growth factor receptor and cyclooxygenase- 2 in carcinomas of the uterine cervix: A potential predictor of poor survival. Clin Cancer Res 10: 1366-1374, 2004. (Pubitemid 38365230)
29. Kulkarni S, Rader JS, Zhang F, Liapis H, Koki AT, Masferrer JL, Subbaramaiah K and Dannenberg AJ: Cyclooxygenase-2 is overexpressed in human cervical cancer. Clin Cancer Res 7: 429-434, 2001. (Pubitemid 32183049)
30. Nahta R, Iglehart JD, Kempkes B and Schmidt EV: Ratelimiting effects of cyclin D1 in transformation by ErbB2 predicts synergy between herceptin and flavopiridol. Cancer Res 62: 2267-2271, 2002. (Pubitemid 34411703)